Numetzah G16%e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Valine, together with the other amino acids in the product, serves as a substrate for protein synthesis and cellular metabolism. When delivered intravenously, it quickly raises plasma amino acid levels, facilitating tissue repair, supporting immune function, and contributing to overall nitrogen balance in the body.

The dose of Numetzah G16%e is determined by the prescribing clinician based on the patient’s weight, clinical condition, and nutritional requirements. Healthcare professionals calculate the appropriate infusion rate and total daily amount to meet individual therapeutic goals.

Safety of Numetzah G16%e in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Numetzah G16%e, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Numetzah G16%e contains a specific blend of essential and conditionally essential amino acids, similar to other parenteral amino acid formulations. Differences may lie in the exact composition, concentration, and manufacturing standards. Clinicians choose a product based on the patient’s nutritional needs, compatibility with other IV fluids, and regulatory approvals.

Numetzah G16%e must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken vigorously. Prior to administration, allow the product to reach room temperature if required by the infusion protocol, and inspect for any particulate matter or discoloration.

Numetzah G16%e is administered intravenously by a qualified healthcare professional. The solution is typically infused through a peripheral or central venous line, using an infusion pump or gravity drip, according to the prescribed rate and total daily volume. Monitoring of vital signs and laboratory parameters is recommended during therapy.

Serious risks include anaphylactic reactions, severe electrolyte disturbances, metabolic acidosis, hyperammonemia in patients with liver dysfunction, and renal impairment. Prompt recognition of these events and immediate medical intervention are essential. Regular laboratory monitoring helps mitigate these risks.

Numetzah G16%e should be avoided in patients with known hypersensitivity to any of its amino acid components, severe uncontrolled electrolyte abnormalities, or untreated severe renal or hepatic failure unless closely monitored. Contraindications are determined by the treating physician based on individual patient factors.